@article {Bousquet:2013:1088-5412:274,
title = "Randomized controlled trial of desloratadine for persistent allergic rhinitis: Correlations between symptom improvement and quality of life",
journal = "Allergy and Asthma Proceedings",
parent_itemid = "infobike://ocean/aap",
publishercode ="ocean",
year = "2013",
volume = "34",
number = "3",
publication date ="2013-05-01T00:00:00",
pages = "274-282",
itemtype = "ARTICLE",
issn = "1088-5412",
eissn = "1539-6304",
url = "https://www.ingentaconnect.com/content/ocean/aap/2013/00000034/00000003/art00013",
doi = "doi:10.2500/aap.2013.34.3668",
keyword = "work productivity, exploratory analyses, desloratadine, persistent allergic rhinitis, placebo-controlled prospective study, quality of life, Pearson product‐moment correlation, Congestion, total five-symptom score",
author = "Bousquet, Jean and Zuberbier, Torsten and Canonica, G. Walter and Fokkens, Wytske J. and Gopalan, Gokul and Shekar, Tulin",
abstract = "Allergic rhinitis (AR) symptoms can impart emotional, quality of life (QOL), and work productivity burdens, especially in persistent AR (PER). Desloratadine, an H1-receptor antagonist, has been shown to be effective against nasal and nonnasal AR symptoms and to improve QOL.
Exploratory analyses were conducted to evaluate whether desloratadine-mediated symptom improvement correlated with improvements in QOL and productivity. The Aerius Control: Clinical and Evaluative Profile of Treatment 2 (NCT00405964) study was a 12-week, multinational, randomized, placebo-controlled
prospective study of once-daily desloratadine at 5 mg in subjects with moderate-to-severe PER. Assessments included twice-daily symptom severity ratings (0 = none to 3 = severe; total and individual symptoms), sleep interference (morning [A.M.]), interference with activities of daily living
(ADL; evening [P.M.]), the Rhinoconjunctivitis Quality of Life QuestionnaireStandardized version (baseline and days 29 and 85), and the Work Productivity and Activity ImpairmentAllergy-Specific questionnaire (baseline and weekly). Pearson productmoment correlation statistics
(r) were determined to assess correlations between symptom score improvements and QOL factors. All desloratadine-treated patients (n = 360) were included in this exploratory analysis. In the desloratadine-treated patients, all correlations tested were positive (all p < 0.0001). The highest
coefficients were seen for the correlations between A.M./P.M. PRIOR total five-symptom score and interference with ADL (r = 0.72) and between A.M. NOW congestion and ADL interference (r = 0.69). Continuous daily treatment of moderate-to-severe PER with desloratadine at 5 mg/day significantly
improved symptoms, which correlated positively, albeit moderately, with QOL benefits and reversal of functional impairments caused by PER.",
}